Hummingbird Bioscience Archives

Home / Posts tagged Hummingbird Bioscience

Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024

SAN FRANCISCO and SINGAPORE, Oct. 23, 2024 (Korea Bizwire) – Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced a poster presentation on HMBD-802, a novel first-in-class dual-payload anti-HER2 antibody-drug conjugate, at the 36th EORTC-NCI-AACR symposium (23-25 October 2024). “We are excited to present at EORTC-NCI-AACR with data demonstrating [...]

Hummingbird Bioscience Announces Key Leadership Appointments

Kon Yew Kwek, BM BCh, DPhil, appointed Chief Medical Officer Lisa Ooi, PhD, appointed Chief Operating Officer SAN FRANCISCO and SINGAPORE, July 29, 2024 (Korea Bizwire) – Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced the internal appointments of Kon Yew Kwek, BM BCh, DPhil, and Lisa [...]

Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024

Data highlights potential of Hummingbird Bioscience’s dual-payload antibody-drug conjugate platform to improve upon the current generation of ADCs SAN FRANCISCO and SINGAPORE, May 13, 2024 (Korea Bizwire) – Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced two presentations at the 20th Annual PEGS Boston summit being held from [...]

George Clinical Selected as CRO for Hummingbird Bioscience’s Phase 1 Oncology Trials in Australia

SYDNEY, May 4 (Korea Bizwire) — George Clinical announces that the company has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is [...]

SK Holdings Invests in Singapore’s Hummingbird Bioscience

SEOUL, May 11 (Korea Bizwire) — SK Holdings Co., the holding firm of South Korean energy and telecoms conglomerate SK Group, said Monday it has invested in Singapore’s Hummingbird Bioscience in the latest move to secure technology for antibody-based medicines. SK Holdings said it has participated as a major investor in the investment worth about [...]